Subgroup analysis of the phase 2 MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory mantle cell lymphoma | Prof Marek Trn?ný at EHA 2015

Subgroup analysis of the phase 2 MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory mantle cell lymphoma | Prof Marek Trn?ný at EHA 2015

EMJ

4 years
705 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) trial of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigators choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay